NXT Biomedical incubator plans to spend $25 million over the next five years on “cutting-edge technologies” designed to address unmet needs, with another $250 million pledged for creation of five to eight startups to be spun out of the incubator.  Each startup will bring to market clinically relevant medical technology carefully designed to improve outcomes and reduce cost to the healthcare system.




Medtech pioneer and NXT Biomedical CEO,  Stanton Rowe, has partnered with investment firm Deerfield Management, to deliver this medical device incubator securing $275 million in funding.